Roth Capital Downgrades Celsion Corp (CLSN) to Neutral

Go back to Roth Capital Downgrades Celsion Corp (CLSN) to Neutral

Celsion (CLSN) Slammed 83% Upon Trade Resumption

January 31, 2013 7:34 AM EST

Celsion Corporation (NASDAQ: CLSN) has resumed trading and is down 83% after ThermoDox Missed Primary Endpoint in Phase III HEAT... More

Celsion (CLSN) will resume trading at 7:30AM after Trial Failure

January 31, 2013 7:27 AM EST

Celsion Corporation (NASDAQ: CLSN) will resume trading at 7:30AM ThermoDox Missed Primary Endpoint in Phase III HEAT... More

Celsion (CLSN) Says ThermoDox Missed Primary Endpoint in Phase III HEAT

January 31, 2013 7:03 AM EST

Celsion Corporation (NASDAQ: CLSN) announced that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer.

Specifically, Celsion has determined, after conferring... More

Celsion (CLSN) to Hold Phase III HEAT Call on Jan. 31; Receives Priority Trial Designation

January 30, 2013 4:15 PM EST

Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Thursday, January 31, 2013 to present the top-line results from its pivotal Phase III HEAT Study with ThermoDox® in combination... More

Celsion (CLSN) trading halted with news pending

January 30, 2013 4:03 PM EST

Celsion Corporation (NASDAQ: CLSN) trading halted with news pending.... More